Last updated on May 2019

Head-to-head Study of Erenumab Against Topiramate in Patients With Episodic Migraine

Brief description of study

The purpose of this study is to determine the safety and efficacy of 70 mg and 140 mg AMG 334 compared to topiramate in the highest tolerated dose in patients suffering from 4 - 14 migraine days/months, who are nave or not suitable for or have previously failed up to three prophylactic migraine treatments.

Clinical Study Identifier: NCT03828539

Find a site near you

Start Over

Novartis Investigative Site

Leipzig, Germany
  Connect »